- Home
- SIGA vs LAB Comparison
SIGA vs LAB Comparison
Compare SIGA & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIGA | LAB |
|---|---|---|
| Founded | 1995 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.8M | 449.9M |
| IPO Year | 1997 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SIGA | LAB |
|---|---|---|
| Price | $6.36 | $1.47 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 374.9K | ★ 2.0M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 9.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $172,249,641.00 | $169,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $132.36 | N/A |
| P/E Ratio | $6.27 | ★ N/A |
| Revenue Growth | N/A | ★ 79.77 |
| 52 Week Low | $4.95 | $0.92 |
| 52 Week High | $9.62 | $2.25 |
Technical Indicators
Market Signals| Indicator | SIGA | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.74 | 61.80 |
| Support Level | $6.13 | $1.44 |
| Resistance Level | $6.55 | $1.51 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 74.31 | 66.67 |
Price Performance
Historical ComparisonAbout SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.